Quick Answer
IGC Pharma, Inc. reported Diluted EPS of $0.09 per share (loss) for fiscal year 2025.
IGC Pharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.09 | +59.1% |
| 2024 | -$0.22 | -214.3% |
| 2017 | -$0.07 | +58.8% |
| 2016 | -$0.17 | +45.2% |
| 2015 | -$0.31 | +16.2% |
| 2014 | -$0.37 | -15.6% |
| 2013 | -$0.32 | +88.0% |
| 2012 | -$2.66 | -98.5% |
| 2011 | -$1.34 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.02 | +0.0% | +0.0% |
| June 30, 2025 | -$0.02 | +33.3% | +0.0% |
| December 31, 2024 | -$0.02 | +77.8% | +0.0% |
| September 30, 2024 | -$0.02 | +60.0% | +33.3% |
| June 30, 2024 | -$0.03 | — | +66.7% |
| December 31, 2023 | -$0.09 | — | -80.0% |
| September 30, 2023 | -$0.05 | — | -150.0% |
| December 31, 2017 | -$0.02 | — | -100.0% |
- IGC Pharma, Inc. showed an increase of +59.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2011–2025 period, IGC Pharma, Inc.’s diluted eps has grown by 93.3% (from $1.34 per share (loss) to $0.09 per share (loss)).
- The most recent figure is from IGC Pharma, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: